直接抗病毒药物持续病毒学应答:对无晚期肝病患者死亡率的影响
该观察性队列分析纳入103,346例无晚期肝病的丙型肝炎病毒单一感染者,评估无干扰素直接抗病毒药物方案获得的持续病毒学应答对全因死亡率的影响。在40,664例接受治疗的患者中,39,374例(96.8%)获得持续病毒学应答,1,290例(3.2%)未获得;另设62,682例未治疗队列。持续病毒学应答患者死亡率为1.18例/100患者年,显著低于未获得应答患者(2.84例/100患者年;P < 0.001)和未治疗患者(3.84例/100患者年;P < 0.001)。
要点
- 无晚期肝病的丙型肝炎患者中,直接抗病毒药物治疗获得持续病毒学应答者死亡率显著低于未获得应答者和未治疗者。
- 多因素Cox模型显示,持续病毒学应答与死亡风险降低独立相关:对比未获得应答者HR 0.44(95%CI 0.32-0.59;P < 0.001),对比未治疗者HR 0.32(95%CI 0.29-0.36;P < 0.001)。
- FIB-4 <1.45和1.45-3.25的持续病毒学应答患者,对比未获得应答者死亡率分别降低46.0%(P = 0.036)和63.2%(P < 0.001)。
核心结论
- 在无临床明显晚期肝病的患者中,用直接抗病毒药物成功治疗丙型肝炎病毒可带来显著的死亡率获益。
研究设计与样本
- 观察性队列分析,数据来自退伍军人事务部丙型肝炎临床病例登记库。
- 共纳入103,346例基因1、2、3型丙型肝炎病毒单一感染者,无晚期肝病定义为FIB-4 ≤3.25且无肝硬化、肝功能失代偿、肝细胞癌诊断或肝移植史。
- 其中40,664例接受无干扰素直接抗病毒药物方案治疗,62,682例构成未治疗队列。
主要发现
- 治疗患者中39,374例(96.8%)获得持续病毒学应答,1,290例(3.2%)未获得。
- 持续病毒学应答患者死亡率为1.18例/100患者年,显著低于未获得应答患者(2.84例/100患者年;P < 0.001)和未治疗患者(3.84例/100患者年;P < 0.001)。
- FIB-4 <1.45的持续病毒学应答患者对比未获得应答患者死亡率降低46.0%(P = 0.036),对比未治疗患者降低66.7%(P < 0.001)。
- FIB-4 1.45-3.25的持续病毒学应答患者对比未获得应答患者死亡率降低63.2%(P < 0.001),对比未治疗患者降低70.6%(P < 0.001)。
- 多因素Cox比例风险模型控制基线人口学、临床特征和合并症后,持续病毒学应答与死亡风险降低独立相关:对比未获得应答者HR 0.44(95%CI 0.32-0.59;P < 0.001),对比未治疗者HR 0.32(95%CI 0.29-0.36;P < 0.001)。
临床怎么用
- 原文结论指出,在无临床明显晚期肝病的患者中,用直接抗病毒药物成功治疗丙型肝炎病毒可转化为显著的死亡率获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The impact of sustained virologic response (SVR) on mortality after direct-acting antiviral (DAA) treatment is not well documented in patients without advanced liver disease and affects access to treatment. This study evaluated the impact of SVR achieved with interferon-free DAA treatment on all-cause mortality in hepatitis C virus-infected patients without advanced liver disease. This observational cohort analysis was comprised of 103,346 genotype 1, 2, and 3, hepatitis C virus-monoinfected patients without advanced liver disease, defined by FIB-4 ≤3.25 and no diagnosis of cirrhosis, hepatic decompensation, or hepatocellular carcinoma or history of liver transplantation, identified from the Veterans Affairs Hepatitis C Clinical Case Registry. Among 40,664 patients treated with interferon-free DAA regimens, 39,374 (96.8%) achieved SVR and 1,290 (3.2%) patients were No SVR; 62,682 patients constituted the untreated cohort. The mortality rate for SVR patients of 1.18 deaths/100 patient-years was significantly lower than the rates for both No SVR patients (2.84 deaths/100 patient-years; P < 0.001) and untreated patients (3.84 deaths/100 patient-years; P < 0.001). SVR patients with FIB-4 <1.45 and 1.45-3.25 had a 46.0% (P = 0.036) and 63.2% (P < 0.001) reduction in mortality rates, respectively, compared to No SVR patients and 66.7% (P < 0.001) and 70.6% (P < 0.001) reduction in mortality rates, respectively, compared to untreated patients. In multivariate Cox proportional hazard models controlling for baseline demographics, clinical characteristics, and comorbidities, SVR was independently associated with reduced risk of death compared to No SVR (hazard ratio, 0.44; 95% confidence interval, 0.32-0.59; P < 0.001) and compared to untreated patients (hazard ratio, 0.32; 95% confidence interval, 0.29-0.36; P < 0.001). CONCLUSION: Successfully treating hepatitis C virus with DAAs in patients without clinically apparent advanced liver disease translates into a significant mortality benefit. (Hepatology 2018).
引用
- Backus LI, Belperio PS, Shahoumian TA, et al. Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease. Hepatology. 2018. PMID: 29377196. doi:10.1002/hep.29811
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。